Skip to content

Nuvalent, Inc. NUVL Return on assets

Return on assets at other companies

Pfizer logo
PfizerPFE
4.6%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-179.8%+218pp
Summit Therapeutics logo
Summit TherapeuticsSMMT
-233.8%-558pp
Exelixis logo
ExelixisEXEL
30.7%+7.9pp
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
-59.4%+270pp
Incyte logo
IncyteINCY
21.9%+21.5pp

Other financials

Income statement

See full
Operating income-$119.4M-25.9%
Net income-$109.3M-29.2%
EPS (diluted)-$1.39-17.8%

Balance sheet

See full
Cash & equivalents$159.7M+32.2%
Total equity$1.2B+16.2%
Total assets$1.3B+20.4%

Cash flow

See full
Operating cash flow-$92.4M-68.5%

Valuation

See full
Market cap$9.77B+58.6%

Returns & leverage

See full
Return on equity-41.2%+7.5pp
Current ratio16.1×+1.7×

Where this comes from

Calculated from Nuvalent, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Nuvalent, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvalent, Inc.'s return on assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvalent, Inc.'s return on assets?
Nuvalent, Inc. (NUVL) reported return on assets of -36.9% in Q1 2026.
How has Nuvalent, Inc.'s return on assets changed year-over-year?
Nuvalent, Inc.'s return on assets decreased by 11.4% year-over-year, from -33.2% to -36.9%.
What is the long-term trend for Nuvalent, Inc.'s return on assets?
Over 4 years (2021 to 2025), Nuvalent, Inc.'s return on assets has grown at a 2.3% compound annual growth rate (CAGR), from -30.4% to -33.3%.
What does return on assets mean?
Trailing-twelve-month net income divided by average total assets. Measures how efficiently the asset base generates profit, independent of how those assets are financed. Computed as net income over average total assets — note this is OpenCapital's standard definition and may differ from data vendors that use alternative numerators.